CAS 103745-39-7
:Fasudil
- (5-Isoquinolinesulfonyl)Homopiperazine
- 1-(5-Isoquinolinesulfonyl)homopiperazine
- 1-(5-Isoquinolinesulphonyl)homopiperazine
- 1-(5-Isoquinolinylsulfonyl)homopiperazine
- 103745-39-7
- 1H-1,4-Diazepine, hexahydro-1-(5-isoquinolinylsulfonyl)-
- 5-(1,4-Diazepan-1-Ylsulfonyl)Isoquinoline Dihydrochloride
- 5-(1,4-Diazepan-1-Ylsulfonyl)Isoquinoline Hydrochloride (1:1)
- 5-(1,4-Diazepan-1-ylsulfonyl)isoquinoline
- 5-[(Hexahydro-1H-1,4-diazepin-1-yl)sulfonyl]isoquinoline
- At 877
- Ha 1077
- Hexahydro-1-(5-isoquinolinesulfonyl)-1H-1,4-diazepine
- N-(5-Isoquinolinesulfonyl)-1,4-perhydrodiazepine
- isoquinoline, 5-[(hexahydro-1H-1,4-diazepin-1-yl)sulfonyl]-
- at877
- HA-1077 DIHYDROCHLORIDE NOVEL VASODILATO R AGE
- 2,3,4,5,6,7-Hexahydro-1-(isoquinolin-5-ylsulfonyl)-1H-1,4-diazepine
- HA 1077, DIHYDROCHLORIDE, 99+%
- 5-(Hexahydro-1H-1,4-diazepine-1-ylsulfonyl)isoquinoline
- FASUDIL
- Hexahydro-1-(5-isoquinolinylsulfonyl)-1H-1,4-diazepine
- HA-1077:Eril
- 1-(5-ISOQUINOLINE-SULFONYL)-HOMOPIPERAZINE
- Vedi altri sinonimi
Fasudil Hydrochloride
CAS:Formula:C14H17N3O2S·HClPurezza:>96.0%(HPLC)(qNMR)Colore e forma:White to Almost white powder to crystalPeso molecolare:327.83Fasudil, 98+%
CAS:HA-1077 dihydrochloride has been shown to be a vasodilating agent as well as a potent inhibitor of Rock-2 (Rho-associated Kinase II), cGKI (cGMP-dependent protein kinase), PKA (cAMP-dependent protein kinase), MYLK, and CaMKII. Rho kinase signaling pathways are thought to cause invasion, migration, a
Formula:C14H17N3O2SPurezza:98+%Peso molecolare:327.835-[(Hexahydro-1H-1,4-diazepin-1-yl)sulfonyl]isoquinoline
CAS:Formula:C14H17N3O2SPurezza:98%Colore e forma:SolidPeso molecolare:291.3687Fasudil
CAS:Formula:C14H17N3O2SPurezza:≥ 98.0%Colore e forma:White to off-white solidPeso molecolare:327.83Fasudil
CAS:Fasudil (HA-1077) is a potent inhibitor of ROCK1, PKA, PKC, and MLCK.Formula:C14H17N3O2SPurezza:99.79% - 99.84%Colore e forma:SolidPeso molecolare:291.37Fasudil
CAS:Fasudil is a rho-kinase inhibitor that prevents the phosphorylation of myosin light chain and inhibits the polymerization of actin, thereby inhibiting cell contraction. Fasudil has been shown to be effective in treating primary pulmonary hypertension by preventing tubulointerstitial injury, as well as in reducing atherosclerotic lesions. It also reduces the expression of growth factor-β1, which may contribute to its therapeutic effects on certain cardiovascular diseases.
Fasudil is available as an injection solution at a concentration of 50mg/mL. It can also be formulated into tablets for oral administration at a dose of 25mg or 50mg per day.Formula:C14H17N3O2SPurezza:Min. 95%Peso molecolare:327.83 g/mol








